中度与轻度治疗性低温对院外心脏骤停昏迷幸存者死亡率和神经结局的影响:CAPITAL CHILL随机临床试验
CAPITAL CHILL是一项单中心、双盲、随机临床优效性试验,纳入389例院外心脏骤停昏迷幸存者,随机分配至31°C(n=193)或34°C(n=196)目标体温管理24小时。主要终点为180天全因死亡或不良神经结局(Disability Rating Scale评分>5)。在纳入主要分析的367例患者中,31°C组主要终点发生率为48.4%,34°C组为45.4%(风险差3.0%,95%CI 7.2%-13.2%;RR 1.07,95%CI 0.86-1.33;结论认为31°C相比34°C未显著改善结局,但研究可能把握度不足。
要点
- 不良事件方面,31°C组深静脉血栓发生率为11.4%,34°C组为10.9%;下腔静脉血栓发生率分别为3.8%和7.7%。
- 19项次要结局中仅ICU住院时间有统计学意义,其余18项无统计学意义;研究可能因样本量不足而未能检出临床重要差异。
适用人群与场景
- 院外心脏骤停后昏迷的幸存者,纳入标准未在原文中详细列出;排除标准原文未提及。
- 研究在加拿大安大略省东部一家三级心脏护理中心进行,场景为急诊/ICU院内温度管理。
诊断标准与关键阈值
- 不良神经结局定义为Disability Rating Scale评分大于5(范围0-29,29为最差结局即植物状态)。
- 主要终点为180天全因死亡或不良神经结局。
- 目标体温管理:31°C或34°C,持续24小时。
处置流程与药物剂量
- 第一步:将院外心脏骤停昏迷幸存者随机分配至目标体温31°C或34°C。
- 第二步:实施目标体温管理,持续24小时。
- 原文未提及具体的降温方法、复温速率、镇静或寒战管理方案,也未提及药物剂量。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心、双盲、随机、临床优效性试验;样本量389例随机(31°C组n=193,34°C组n=196),主要分析纳入367例(平均年龄61岁,女性69例[19%]),366例(99.7%)完成试验。
- 干预与对照:目标体温31°C vs 34°C,持续24小时。
- 不良事件:深静脉血栓31°C组11.4% vs 34°C组10.9%;下腔静脉血栓31°C组3.8% vs 34°C组7.7%。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),单中心、双盲、优效性设计。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心研究;样本量可能不足以检测临床重要差异(原文结论指出研究可能把握度不足);原文未提及其他局限。
对床旁实践的改变
- 对于院外心脏骤停昏迷幸存者,采用31°C目标温度管理相比34°C并未改善180天死亡或神经结局,因此不支持常规将目标温度降至31°C。
- 31°C组ICU住院时间更长(中位数10天 vs 7天),在资源分配时需考虑。
- 研究可能把握度不足,不能完全排除31°C的潜在获益或危害;临床决策应结合个体情况。
- 适用人群为院外心脏骤停昏迷幸存者;不适用人群原文未提及。
指南或共识出处
- CAPITAL CHILL随机临床试验,发表于JAMA;试验注册号ClinicalTrials.gov Identifier: NCT02011568。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Comatose survivors of out-of-hospital cardiac arrest experience high rates of death and severe neurologic injury. Current guidelines recommend targeted temperature management at 32 °C to 36 °C for 24 hours. However, small studies suggest a potential benefit of targeting lower body temperatures.
OBJECTIVE: To determine whether moderate hypothermia (31 °C), compared with mild hypothermia (34 °C), improves clinical outcomes in comatose survivors of out-of-hospital cardiac arrest.
DESIGN, SETTING, AND PARTICIPANTS: Single-center, double-blind, randomized, clinical superiority trial carried out in a tertiary cardiac care center in eastern Ontario, Canada. A total of 389 patients with out-of-hospital cardiac arrest were enrolled between August 4, 2013, and March 20, 2020, with final follow-up on October 15, 2020.
INTERVENTIONS: Patients were randomly assigned to temperature management with a target body temperature of 31 °C (n = 193) or 34 °C (n = 196) for a period of 24 hours.
MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality or poor neurologic outcome at 180 days. Neurologic outcome was assessed using the Disability Rating Scale, with poor neurologic outcome defined as a score greater than 5 (range, 0-29, with 29 being the worst outcome [vegetative state]). There were 19 secondary outcomes, including mortality at 180 days and length of stay in the intensive care unit.
RESULTS: Among 367 patients included in the primary analysis (mean age, 61 years; 69 women [19%]), 366 (99.7%) completed the trial. The primary outcome occurred in 89 of 184 patients (48.4%) in the 31 °C group and in 83 of 183 patients (45.4%) in the 34 °C group (risk difference, 3.0% [95% CI, 7.2%-13.2%]; relative risk, 1.07 [95% CI, 0.86-1.33]; P = .56). Of the 19 secondary outcomes, 18 were not statistically significant. Mortality at 180 days was 43.5% and 41.0% in patients treated with a target temperature of 31 °C and 34 °C, respectively (P = .63). The median length of stay in the intensive care unit was longer in the 31 °C group (10 vs 7 days; P = .004). Among adverse events in the 31 °C group vs the 34 °C group, deep vein thrombosis occurred in 11.4% vs 10.9% and thrombus in the inferior vena cava occurred in 3.8% and 7.7%, respectively.
CONCLUSIONS AND RELEVANCE: In comatose survivors of out-of-hospital cardiac arrest, a target temperature of 31 °C did not significantly reduce the rate of death or poor neurologic outcome at 180 days compared with a target temperature of 34 °C. However, the study may have been underpowered to detect a clinically important difference.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02011568.
参考来源
- Le May M, Osborne C, Russo J, et al. Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial. JAMA. 2021. PMID: 34665203. doi:10.1001/jama.2021.15703
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。